3320 Stock Overview
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
China Resources Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.06 |
| 52 Week High | HK$7.11 |
| 52 Week Low | HK$4.61 |
| Beta | 0.092 |
| 1 Month Change | 1.40% |
| 3 Month Change | -7.66% |
| 1 Year Change | -14.96% |
| 3 Year Change | 16.86% |
| 5 Year Change | 22.22% |
| Change since IPO | -43.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3320 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 2.2% | 10.1% | 1.4% |
| 1Y | -15.0% | 22.3% | 15.4% |
Return vs Industry: 3320 underperformed the Hong Kong Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: 3320 underperformed the Hong Kong Market which returned 14.8% over the past year.
Price Volatility
| 3320 volatility | |
|---|---|
| 3320 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in HK Market | 15.2% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 3320 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3320's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 72,700 | n/a | www.crpharm.com |
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis.
China Resources Pharmaceutical Group Limited Fundamentals Summary
| 3320 fundamental statistics | |
|---|---|
| Market cap | HK$31.79b |
| Earnings (TTM) | HK$3.62b |
| Revenue (TTM) | HK$279.83b |
Is 3320 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3320 income statement (TTM) | |
|---|---|
| Revenue | CN¥257.67b |
| Cost of Revenue | CN¥216.98b |
| Gross Profit | CN¥40.69b |
| Other Expenses | CN¥37.36b |
| Earnings | CN¥3.33b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.53 |
| Gross Margin | 15.79% |
| Net Profit Margin | 1.29% |
| Debt/Equity Ratio | 69.0% |
How did 3320 perform over the long term?
See historical performance and comparisonDividends
Does 3320 pay a reliable dividends?
See 3320 dividend history and benchmarks| China Resources Pharmaceutical Group dividend dates | |
|---|---|
| Ex Dividend Date | May 28 2025 |
| Dividend Pay Date | Jul 14 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 52 days |
Does 3320 pay a reliable dividends?
See 3320 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 04:55 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Resources Pharmaceutical Group Limited is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Zhishun Siu | CCB International Securities Limited |
| Yanyin Zhu | China International Capital Corporation Limited |